Dr. Gil Kliman joined InterWest's life sciences team in 1996. He invests in a broad array of life sciences opportunities with a special interest in ophthalmology, medical devices, and healthcare IT. He is a board member of Autonomic Technologies, Doximity, Glaukos, On Demand Therapeutics, Restoration Robotics, and ReVision Optics. He was an early investor in IntraLase and LenSx, two pioneering ophthalmic laser companies that led transformative advances in eye surgery around the world.

Prior to InterWest, Gil was a health care investor at TA Associates and at Norwest Venture Capital. A former practicing ophthalmologist and laser researcher, he was previously west coast director of LCA Vision, and served as an assistant professor at Tufts New England Eye Center and on the clinical faculty at Massachusetts Eye and Ear Infirmary.

Gil has a B.A. from Harvard University. He received an M.D. from the University of Pennsylvania and an M.B.A. from Stanford University. He completed an ophthalmology residency at Wills Eye Institute and retina fellowship at Massachusetts Eye and Ear Infirmary as a Heed Fellow. He also serves as a National Trustee for the Foundation Fighting Blindness.

Prior Investments

Epocrates (Acquired by Athena Health in 2013),  INC Research (Acquired by Avista Capital Partners in 2010), Inspire Pharmaceuticals (IPO 2000, ISPH) IntraLase (IPO 2004, ILSE), LenSx Lasers (Acquired by Alcon in 2010), Spinal Dynamics (Acquired by Medtronic in 2002)